Erratum to Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival Tamoxifen Resistance [Neoplasia, 16, 5, (2014), 390-402] DOI: 10.1016/j.neo.2014.05.007;Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance

Neoplasia (United States)

Volumn 16, Issue 5, 2014, Pages 390-402

  Putluri, Nagireddy ^a   Maity, Suman ^a   Kommagani, Ramakrishna ^a   Creighton, Chad J ^a   Putluri, Vasanta ^a   Chen, Fengju ^a   Nanda, Sarmishta ^b   Bhowmik, Salil Kumar ^a   Terunuma, Atsushi ^c   Dorsey, Tiffany ^c   Nardone, Agostina ^b   Fu, Xiaoyong ^b   Shaw, Chad ^a   Sarkar, Tapasree Roy ^a   Schiff, Rachel ^a,b   Lydon, John P ^a   O'Malley, Bert W ^a   Ambs, Stefan ^c   Das, Gokul M ^d   Michailidis, George ^e   Sreekumar, Arun ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIMIDINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M2; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; DRUG PROTEIN BINDING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIMIDINE METABOLISM; TISSUE MICROARRAY; TUMOR XENOGRAFT;

EID: 84924595580     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.07.006     Document Type: Erratum

References (73)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63(1):181-187.
3. McKinney C.D., Frierson H.F., Fechner R.E., Wilhelm M.C., Edge S.B. Pathologic findings in nonpalpable invasive breast cancer. Am J Surg Pathol 1992, 16(1):33-36.
4. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., Fumoleau P., Jones S., Lui W.Y., Mauriac L., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823.
5. Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., Renta V., Fronda G., Preisler H.D. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002, 8(4):1061-1067.
6. Toft D.J., Cryns V.L. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 2011, 25:199-211.
7. Niida A., Smith A.D., Imoto S., Aburatani H., Zhang M.Q., Akiyama T. Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinforma 2009, 10:71.
8. Finnegan T.J., Carey L.A. Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 2007, 3(1):55-63.
9. Kang S., Kim M.J., An H., Kim B.G., Choi Y.P., Kang K.S., Gao M.Q., Park H., Na H.J., Kim H.K., et al. Proteomic molecular portrait of interface zone in breast cancer. J Proteome Res 2010, 9:5638-5645.
10. Cha S., Imielinski M.B., Rejtar T., Richardson E.A., Thakur D., Sgroi D.C., Karger B.L. In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology. Mol Cell Proteomics 2010, 9:2529-2544.
11. Rauser S.Marquardt C., Balluff B., Deininger S.O., Albers C., Belau E., Hartmer R., Suckau D., Specht K., Ebert M.P., et al. Classification of HER-2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 2010, 9:1854-1863.
12. He J., Shen D., Chung D.U., Saxton R.E., Whitelegge J.P., Faull K.F., Chang H.R. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol 2009, 35(4):683-692.
13. Li J., Gromov P., Gromova I., Moreira J.M., Timmermans-Wielenga V., Rank F., Wang K., Li S., Li H., Wiuf C., et al. Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics 2008, 8(23-24):5038-5052.
14. Datta S. Classification of breast cancer versus normal samples from mass spectrometry profiles using linear discriminant analysis of important features selected by random forest. Stat Appl Genet Mol Biol 2008, 7(2). [Article7].
15. Laronga C., Drake R.R. Proteomic approach to breast cancer. Cancer Control 2007, 14(4):360-368.
16. Nakagawa T., Huang S.K., Martinez S.R., Tran A.N., Elashoff D., Ye X., Turner R.R., Giuliano A.E., Hoon D.S. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis. Cancer Res 2006, 66(24):11825-11830.
17. Nagaraja G.M., Othman M., Fox B.P., Alsaber R., Pellegrino C.M., Zeng Y., Khanna R., Tamburini P., Swaroop A., Kandpal R.P. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006, 25(16):2328-2338.
18. Carr K.M., Rosenblatt K, Petricoin EF, Liotta LA Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics 2004, 1(2):134-140.
19. Claudino W.M., Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007, 25(19):2840-2846.
20. Gowda G.A., Zhang S., Gu H., Asiago V., Shanaiah N., Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008, 8(5):617-633.
21. Oakman C., Tenori L., Claudino W.M., Cappadona S., Nepi S., Battaglia A., Bernini P., Zafarana E., Saccenti E., Fornier M., et al. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann Oncol 2011, 22(6):1295-1301.
22. Cheng L.L., Chang I.W., Smith B.L., Gonzalez R.G. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 1998, 135(1):194-202.
23. Sitter B., Sonnewald U., Spraul M., Fjösne H.E., Gribbestad I.S. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002, 15(5):327-337.
24. Bathen T.F., Jensen L.R., Sitter B., Fjösne H.E., Halgunset J., Axelson D.E., Gribbestad I.S., Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2007, 104(2):181-189.
25. Sitter B., Lundgren S., Bathen T.F., Halgunset J., Fjosne H.E., Gribbestad I.S. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006, 19(1):30-40.
26. Yang C., Richardson AD, Smith JW, Osterman A Comparative metabolomics of breast cancer. Pac Symp Biocomput 2007, 181-192.
27. Locasale J.W., Grassian A.R., Melman T., Lyssiotis C.A., Mattaini K.R., Bass A.J., Heffron G., Metallo C.M., Muranen T., Sharfi H., et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011, 43(9):869-874.
28. Possemato R., Marks K.M., Shaul Y.D., Pacold M.E., Kim D., Birsoy K., Sethumadhavan S., Woo H.K., Jang H.G., Jha A.K., et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011, 476(7360):346-350.
29. Putluri N., Shojaie A., Vasu V.T., Nalluri S., Vareed S.K., Putluri V., Vivekanandan-Giri A., Byun J., Pennathur S., Sana T.R., et al. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One 2011, 6(7):e21417.
30. Putluri N., Shojaie A., Vasu V.T., Vareed S.K., Nalluri S., Putluri V., Thangjam G.S., Panzitt K., Tallman C.T., Butler C., et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011, 71(24):7376-7386.
31. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457(7231):910-914.
32. Vareed S.K., Bhat V.B., Thompson C., Vasu V.T., Fermin D., Choi H., Creighton C.J., Gayatri S., Lan L., Putluri N., et al. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PLoS One 2011, 6(3):e17177.
33. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
34. Efron B., Tibshirani R. On testing the significance of sets of genes. Ann Appl Stat 2007, 107-129.
35. Morrison G., Fu X., Shea M, Nanda S, Giuliano M, Wang T, Klinowska T, Osborne CK, Rimawi MF, Schiff R Therapeutic potential of the dual EGFR/HER-2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat 2014, 144(2):263-272.
36. Zhang Y., Tseng CC, Tsai YL, Fu X., Schiff R, Lee AS Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One 2013, 8(11):e80071.
37. R: a language and environment for statistical computing 2008, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria, [ISBN 3-900051-07-0, URL http://www.R-project.org.].
38. Wong J. Imputation: imputation. R package version 1.3 http://CRAN.R-project.org/package=imputation.
39. Terunuma A., Putluri N., Mishra P., Mathé E.A., Dorsey T.H., Yi M., Wallace T.A., Issaq H.J., Zhou M., Killian J.K., et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014, 124(1):398-412.
40. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 57:289-300.
41. Xiao Y., Yang J.Y.H. Differential Expression via Distance Summary for Microarray Data R package version 1.30.0 2007.
42. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., Speed T.P. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264.
43. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
44. Bolker B., et al. gplots: various R programming tools for plotting data. R Package Version 2.10.1 2011, G. Warnes (Ed.).
45. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102(43):15545-15550.
46. Tibshirani R., Efron B. GSA: Gene set analysis. R package version 1.03 http://CRAN.R-project.org/package=GSA.
47. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
48. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Sci Signal 2012, 335(6066):348-353.
49. Creighton C.J. The molecular profile of luminal B breast cancer. Biologics 2012, 6:289-297.
50. Kommagani R., Szwarc M.M., Kovanci E., Gibbons W.E., Putluri N., Maity S., Creighton C.J., Sreekumar A., DeMayo F.J., Lydon J.P., et al. Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization. PLoS Genet 2013, 9:e1003900.
51. Kanehisa M., Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 2000, 28(1):27-30.
52. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., Parker J.S., Luo J., DeSchryver K., Allred D.C., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011, 29(17):2342-2349.
53. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., et al. Ki67 index, HER-2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
54. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
55. Slodkowska E.A., Ross J.S. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009, 9(5):417-422.
56. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25(10):1239-1246.
57. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F., et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9(1):239.
58. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68(3):826-833.
59. Fu L., Qiu W., Yu Y., Guo Y., Zhao P., Zhang X., Liu C., Li F., Huang H., Huang M., et al. Clinical and molecular genetic study of infantile-onset Pompe disease in Chinese patients: identification of 6 novel mutations. Gene 2014, 535(1):53-59.
60. Aimiuwu J., Wang H., Chen P., Xie Z., Wang J., Liu S., Klisovic R., Mims A., Blum W., Marcucci G., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012, 119(22):5229-5238.
61. Chan R., Wong M.S. Differential regulation of cyclic AMP synthesis by estrogen in MCF7 cells. Biochem Biophys Res Commun 2007, 363(3):616-620.
62. Keller P.J., Lin A.F., Arendt L.M., Klebba I., Jones A.D., Rudnick J.A., DiMeo T.A., Gilmore H., Jefferson D.M., Graham R.A., et al. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res 2010, 12(5):R87.
63. Kristensen V.N., Vaske C.J., Ursini-Siegel J., Van Loo P., Nordgard S.H., Sachidanandam R., Sørlie T., Wärnberg F., Haakensen V.D., Helland Å., et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012, 109(8):2802-2807.
64. Hirai M.Y., Yano M., Goodenowe D.B., Kanaya S., Kimura T., Awazuhara M., Arita M., Fujiwara T., Saito K. Integration of transcriptomics and metabolomics for understanding of global responses to nutritional stresses in Arabidopsis thaliana. Proc Natl Acad Sci U S A 2004, 101(27):10205-10210.
65. Imielinski M., Cha S., Rejtar T., Richardson E.A., Karger B.L., Sgroi D.C. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteomics 2012, 11(6). [M111 014910].
66. Furuta E., Okuda H., Kobayashi A., Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010, 1805(2):141-152.
67. Mercier I., Casimiro M.C., Wang C., Rosenberg A.L., Quong J., Minkeu A., Allen K.G., Danilo C., Sotgia F., Bonuccelli G., et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther 2008, 7(8):1212-1225.
68. Peppercorn J., Perou C.M., Carey L.A. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 2008, 26(1):1-10.
69. Creighton C.J., Massarweh S., Huang S., Tsimelzon A., Hilsenbeck S.G., Osborne C.K., Shou J., Malorni L., Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008, 68(18):7493-7501.
70. Shah K.N., Mehta K.R., Peterson D., Evangelista M., Livesey J.C., Faridi J.S. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res 2014, 12(3):394-407.
71. Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., Kalyana-Sundaram S., Wang R., Ning Y., Hodges L., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013, 45(12):1446-1451.
72. Fuqua S.A., Gu G., Rechoum Y. Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 2014, 144(1):11-19.
73. Aird K.M., Zhang G., Li H., Tu Z., Bitler B.G., Garipov A., Wu H., Wei Z., Wagner S.N., Herlyn M., et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep 2013, 3(4):1252-1265.